Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53

Pharmacological Research

Volumn 58, Issue 3-4, 2008, Pages 247-256

  Chan, Kuei Chuan ^a   Wang, Chau Jong ^b   Ho, Hsieh Hsun ^b   Chen, Hsiang Mei ^b   Huang, Chien Ning ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cyclin dependent kinase inhibitors; High glucose; p53; Simvastatin; Vascular smooth muscle cell

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLUCOSE; PROTEIN P21; PROTEIN P27; PROTEIN P53; SIMVASTATIN;

ANIMAL CELL; AORTA MEDIA; ARTICLE; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GROWTH INHIBITION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; AORTA, THORACIC; BENZOTHIAZOLES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; FLOW CYTOMETRY; GLUCOSE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOPRECIPITATION; MYOCYTES, SMOOTH MUSCLE; RATS; SIMVASTATIN; TETRAZOLIUM SALTS; THIAZOLES; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 54349096517     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.08.005     Document Type: Article

References (50)

1. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
2. Konishi A., and Berk B.C. Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J Biol Chem 278 (2003) 35049-35056
3. Campbell M., Allen W.E., Sawyer C., Vanhaesebroeck B., and Trimble E.R. Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ Res 95 (2004) 380-388
4. Graier W.F., Grubenthal I., Dittrich P., Wascher T.C., and Kostner G.M. Intracellular mechanism of high d-glucose-induced modulation of vascular cell proliferation. Eur J Pharmacol 294 (1995) 221-229
5. Hattori Y., Hattori S., Sato N., and Kasai K. High-glucose-induced nuclear factor KB activation in vascular smooth muscle cells. Cardiovasc Res 46 (2000) 188-197
6. Hao F., and Yu J.D. High glucose enhance expression of matrix metalloproteinase-2 in smooth muscle cells. Acta Pharmacol Sin 24 (2003) 534-538
7. Barsness G.W., Peterson E.D., Ohman E.M., et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 96 (1997) 2551-2556
8. Cutlip E.D., Chauhan M.S., Baim D.S., et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 40 (2002) 2082-2089
9. Haunstetter A., Izumo S., and Apoptosis. Basic mechanisms and implications for cardiovascular disease. Circ Res 82 (1998) 1111-1129
10. Erl W., Hristov M., Neureuter M., Yan Z.Q., Hansson G.K., and Weber P.C. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis 169 (2003) 251-258
11. Corpataux J.M., Naik J., Porter K.E., and London N.J. The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. J Surg Res 129 (2005) 52-56
12. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47 (2000) 648-657
13. Koh K.K., Cardillo C., Bui M.N., et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 99 (1999) 354-360
14. Merten M., Dong J.F., Lopez J.A., and Thiagarajan P. Cholesterol sulfate: a new adhesive molecule for patients. Circulation 103 (2001) 2032-2034
15. Notarbartolo A., Davi G., Averna M., et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 15 (1995) 247-251
16. Lacoste L., Lam J.Y., Hung J., Letchacovski G., Solymoss C.B., and Waters D. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 92 (1995) 3172-3177
17. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
18. Strandberg T.E., Vanhanen H., and Tikkanen M.J. Effects of statins on C-reactive protein in patients with coronary artery disease. Lancet 353 (1999) 188-189
19. Kluft C., de Maat M.P., Gevers Leuven J.A., Potter van Loon B.J., and Mohrschladt M.F. Statins and C-reactive protein. Lancet 353 (1999) 1274
20. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) investigators. Circulation 100 (1999) 230-235
21. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., and Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84 (1999) 413-428
22. Porter K.E., Naik J., Turner N.A., Dickinson T., Thompson M.M., and London N.J. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 36 (2002) 150-157
23. Inoue T., and Node K. Statin therapy for vascular failure. Cardiovasc Drugs Ther 21 (2007) 281-295
24. Srivastava S., Ramana K.V., Tammali R., Srivastava S.K., and Bhatnagar A. Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells. Diabetes 55 (2006) 901-910
25. Fontos G. Drug-eluting coronary stents. Orv Hetil 147 (2006) 2059-2066
26. Wessely R., Schomig A., and Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 47 (2006) 708-714
27. Down J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1515-1522
28. Rosenson R.S., and Tangney C.C. Anti-atherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 (1998) 1543-1550
29. Dunzendorfer S., Rothbucher D., Schratzberger P., Reinisch N., Kahler C.M., and Wiedermann C.J. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 81 (1997) 963-969
30. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
31. Mintz G.S., Popma J.J., Pichard A.D., et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 94 (1996) 35-43
32. Liao J.K. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 86 (2002) 5-18
33. Wang W., Wang P.F., Sheng Z.F., Fang J.Z., and Liu F.Y. Effect of simvastatin on the proliferation of human omental preadipocytes and caspase-3 expression. Zhong Nan Da Xue Xue Bao Yi Xue Ban 30 (2005) 673-676
34. Erl W. Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis?. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 135-144
35. Kozai T., Eto M., Yang Z., Shimokawa H., and Luscher T.F. Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway. Cardiovasc Res 68 (2005) 475-482
36. Sakamoto K., Murata T., Chuma H., Hori M., and Ozaki H. Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen-activated protein kinase inactivation in organ-cultured artery. Arterioscler Thromb Vasc Biol 25 (2005) 327-333
37. Ambrosi P., Villani P., Habib G., and Bouvenot G. The statins: new properties. Therapie 58 (2003) 15-21
38. Kumai T., Matsumoto N., Koitabashi Y., et al. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels. Curr Med Chem Cardiovasc Hematol Agents 3 (2005) 195-201
39. Jacks T., and Weinberg R.A. Cell-cycle control and its watchman. Nature 381 (1996) 643-644
40. Collins K., Jacks T., and Pavletich N.P. The cell cycle and cancer. Proc Natl Acad Sci USA 94 (1997) 2776-2778
41. Lee B., Kim C.H., and Moon S.K. Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells. FEBS Lett 580 (2006) 5177-5184
42. Vidal A., and Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene 247 (2000) 1-15
43. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
44. Nie L., Wise M., Peterson D., and Meydani M. Mechanism by which avenanthramide-c, a polyphenol of oats, blocks cell cycle progression in vascular smooth muscle cell. Free Radic Biol Med 41 (2006) 702-708
45. Meerson A., Milyavsky M., and Rotter V. p53 mediates density-dependent growth arrest. FEBS Lett 559 (2004) 152-158
46. Kip1. J Biol Chem 274 (1999) 21926-21931
47. Rao S., Lowe M., Herliczek T.W., and Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17 (1998) 2393-2402
48. Sindermann J.R., Fan L., Weigel K.A., et al. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis 150 (2000) 331-341
49. Gudas J.M., Oka M., Diella F., Trepel J., and Cowan K.H. Expression of wild-type p53 during the cell cycle in normal human mammary epithelial cells. Cell Growth Differ 5 (1994) 295-304
50. Donovan J., and Slingerland J. Transforming growth factor-β and breast cancer cell cycle arrest by transforming growth factor-β and its disruption in cancer. Breast Cancer Res 2 (2000) 116-124